SUPERNUS PHARMACEUTICALS, INC.
SUPNUS売上高
$719M
百万USD
営業利益
$-62M
百万USD
純利益
$-39M
百万USD
ROE
-3.6%
最新FY
EPS
$-0.68
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $131M | $6M | $0.11 |
| FY2021 | Q2 | $141M | $24M | $0.43 |
| FY2021 | Q3 | $148M | $22M | $0.40 |
| FY2021 | FY | $580M | $53M | $0.98 |
| FY2022 | Q1 | $153M | $26M | $0.43 |
| FY2022 | Q2 | $170M | $8M | $0.14 |
| FY2022 | Q3 | $177M | $2M | $0.03 |
| FY2022 | FY | $667M | $61M | $1.04 |
| FY2023 | Q1 | $154M | $17M | $0.29 |
| FY2023 | Q2 | $136M | $-1M | $-0.02 |
| FY2023 | Q3 | $154M | $-16M | $-0.29 |
| FY2024 | Q1 | $144M | $0M | $0.00 |
| FY2024 | Q2 | $168M | $20M | $0.36 |
| FY2024 | Q3 | $176M | $38M | $0.69 |
| FY2024 | FY | $662M | $74M | $1.32 |
| FY2025 | Q1 | $150M | $-12M | $-0.21 |
| FY2025 | Q2 | $165M | $22M | $0.40 |
| FY2025 | Q3 | $192M | $-45M | $-0.80 |
| FY2025 | FY | $719M | $-39M | $-0.68 |
| FY2026 | Q1 | $208M | $-2M | $-0.04 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | - | - | $520M | $580M | $667M | $662M | $719M |
| 営業利益 | $54M | $100M | $144M | $149M | $174M | $86M | $46M | $82M | $-62M |
| 純利益 | $91M | $57M | $111M | $113M | $127M | $53M | $61M | $74M | $-39M |
| 総資産 | $310M | $424M | $978M | $1.2B | $1.5B | $1.7B | $1.7B | $1.4B | $1.5B |
| 純資産 | - | - | - | - | - | - | - | - | - |
| 自己資本 | $192M | $267M | $453M | $595M | $745M | $816M | $886M | $1.0B | $1.1B |
| 営業CF | - | $115M | $129M | $143M | $138M | $127M | $117M | $172M | $47M |
| EPS | $1.76 | $1.08 | $2.05 | $2.10 | $2.36 | $0.98 | $1.04 | $1.32 | $-0.68 |
| BPS | $3.82 | $5.19 | $8.66 | $11.33 | $14.07 | $15.28 | $16.30 | $18.56 | $18.44 |
| ROE | 47.6% | 21.4% | 24.5% | 19.0% | 17.0% | 6.5% | 6.9% | 7.1% | -3.6% |